Objectives: Neoadjuvant chemotherapy (NACT) versus primary debulking surgery (PDS) for advanced epithelial ovarian cancer (AEOC) remains controversial in the United States. Generalizability of existing trial results has been criticized because of less aggressive debulking procedures than commonly used in the United States. As a result, economic evaluations using input data from these trials may not accurately reflect costs and outcomes associated with more aggressive primary surgery. Using data from an ongoing trial performing aggressive debulking, we investigated the cost-effectiveness and cost-utility of NACT versus PDS for AEOC. Methods: A decision tree model was constructed to estimate differences in short-term outcomes and costs for a hypothetical cohort of 15,000 AEOC patients (US annual incidence of AEOC) treated with NACT versus PDS over a 1-year time horizon from a Medicare payer perspective. Outcomes included costs per cancer-related death averted, life-years and quality-adjusted life-years (QALYs) gained. Base-case probabilities, costs, and utilities were based on the Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasms trial. Base-case analyses assumed equivalent survival; threshold analysis estimated the maximum survival difference that would result in NACT being cost-effective at $50,000/QALYand $100,000/QALY willingness-to-pay thresholds. Probabilistic sensitivity analysis was used to characterize model uncertainty. Results: Compared with PDS, NACT was associated with $142 million in cost savings, 1098 fewer cancer-related deaths, and 1355 life-years and 1715 QALYs gained, making it the dominant treatment strategy for all outcomes. In sensitivity analysis, NACT remained dominant in 99.3% of simulations. Neoadjuvant chemotherapy remained cost-effective at $50,000/QALY and $100,000/QALY willingness-to-pay thresholds if survival differences were less than 2.7 and 1.4 months, respectively. Conclusions: In the short term, NACT is cost-saving with improved outcomes. However, if PDS provides a longer-term survival advantage, it may be cost-effective. Research is needed on the role of patient preferences in tradeoffs between survival and quality of life.
O varian cancer is the fifth leading cause of cancer-related death among women, largely due to the majority of cases being diagnosed at advanced stage. 1, 2 The standard treatment for advanced ovarian cancer in the United States has traditionally been primary debulking surgery (PDS), which aims to remove the majority of tumor burden upfront, followed by adjuvant chemotherapy (ACT). Primary debulking surgery that results in minimal to no residual disease is an important predictor of survival. 3Y11 However, achieving optimal cytoreduction with PDS often requires radical surgery that can be associated with substantial morbidity, including postoperative complications that can delay chemotherapy initiation and decrease overall survival. 4,12Y14 An alternative treatment approach is neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) and ACT. Neoadjuvant chemotherapy aims to reduce the tumor burden prior to surgery, which can decrease the need for aggressive procedures. This reduces the risk of postoperative morbidity that can result in costly hospital readmissions and decrements to quality of life. Accordingly, NACT may be a cost-saving treatment alternative if patients treated with NACT have comparable overall survival to patients treated with PDS.
The comparative effectiveness of NACT versus PDS in terms of overall survival remains controversial in the United States. 15Y21 Among women with advanced epithelial ovarian cancer (AEOC), 2 phase 3 randomized trials conducted in the United Kingdom and Europe observed noninferior survival with NACT compared with PDS. 22, 23 However, the generalizability of these studies to US practice has been questioned because of shorter median overall survival and lower rates of optimal debulking among PDS patients than typically seen in the large US centers. 16 For instance, in the European Organisation for Research and Treatment of Cancer (EORTC) 55971 trial, only 42% of PDS patients were optimally debulked, whereas optimal debulking rates of 75% are commonly reported at US centers. 16 These differences may result from more aggressive surgical approaches commonly used in the United States. Without existing evidence from an aggressive surgical setting, the role of NACT for AEOC in the United States is widely disputed.
15Y21
Currently, a phase 3 superiority trial is being conducted in Italy (Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasms [SCORPION] ), comparing NACT to PDS among women with bulky AEOC. This trial is using more aggressive surgery, with optimal debulking rates more comparable to those in the United States. 24 Although overall survival outcomes have not yet been reported, results of postoperative outcomes indicate that NACT patients experienced significantly fewer early and late postoperative complications and reported significantly better quality of life, compared with patients who received PDS.
These results represent the first randomized trial data on shortterm morbidity and mortality between NACT and PDS in a population that has undergone aggressive debulking surgery.
In the absence of conclusive evidence on the effectiveness of NACT versus PDS in terms of overall survival, cost-utility analyses of short-term outcomes may help inform decision making among women for whom the ideal treatment is unclear. Although prior studies 25 have investigated the costutility of NACT using data from trials such as EORTC 55971, analyses using data from trials performing aggressive debulking surgery are needed in order for results to be relevant to clinical decision making in the United States. To that end, the objectives of the present study were to (1) estimate the costeffectiveness and cost-utility of NACT versus PDS for stages IIICYIVAEOC patients using an aggressive surgical approach and (2) estimate the maximum difference in overall survival between NACT and PDS at which NACT would remain costeffective at $50,000/quality-adjusted life-year (QALY) and $100,000/QALY willingness-to-pay (WTP) thresholds.
MATERIALS AND METHODS
A decision tree model was constructed to estimate differences in grades IIIYV perioperative and postoperative complications and costs for a hypothetical cohort of 15,000 AEOC patients over a 1-year time horizon from a US Medicare payer perspective (Fig. 1) . With nearly half of ovarian cancer cases occurring in women 65 years or older, Medicare represents a major US payer in the treatment of this disease. 2 A cohort size of 15,000 was chosen based on the estimated annual incidence of advanced-stage epithelial ovarian cancer in the United States. 2, 26, 27 Women in the hypothetical cohort received either PDS followed by 6 rounds of adjuvant intravenous (IV) paclitaxel/carboplatin 28 or 3 rounds of neoadjuvant IV paclitaxel/carboplatin followed by IDS and an additional 3 rounds of adjuvant IV paclitaxel/carboplatin. Treatment with IV chemotherapy was assumed in both arms based on treatment received in the SCORPION trial. This is consistent with limited uptake of intraperitoneal chemotherapy in the United States outside major centers.
29Y32
For each treatment alternative in the decision tree, we estimated the cohort-level treatment costs, number of ovarian cancer/related deaths, and survival time in life-years and QALYs that would be observed if all 15,000 women in the hypothetical cohort received a given treatment (NACT or PDS). Quality-adjusted life-years represent the time spent in a particular health state (eg, postoperative complications), weighted using utilities that reflect the quality of life associated with that health state. Utility weights range from 0 to 1, with 0 representing the worst health state (eg, death) and 1 representing the utility associated with perfect health. FIGURE 1. Decision tree comparing NACT to PDS for bulky advanced ovarian cancer. The decision tree presented here describes the potential experiences of bulky AEOC patients who receive either PDS followed by ACT or NACT followed by IDS. Patients move left to right through the tree. The square node represents the decision to treat patients with PDS or NACT. Circle nodes represent the chance of a given outcome; triangle nodes represent a terminal event. *Early complications include those occurring at 30 days or less postsurgery; late complications include those occurring 1 to 6 months postsurgery. Estimation of outcomes is described below. These outcomes were then used to calculate incremental cost-effectiveness ratios, representing the cost per life-year gained, cost per QALY gained, and cost per short-term ovarian cancerYrelated death averted, associated with treatment with NACT relative to treatment with PDS.
Event Probabilities
Base-case event probabilities were based on results reported in the SCORPION trial (Table 1) . 24 The SCORPION trial was selected as it is the currently available randomized trial in which the most aggressive surgical approach was taken. The probability of optimal debulking was assumed to be equal to that achieved in the SCORPION trial; specifically, 46% and 58% of patients who received PDS and NACT, respectively, had no gross residual disease, and 46% and 33% of PDS and NACT patients, respectively, had 0.1-to 1-cm residual disease. 24 Patients treated with NACT who did not undergo IDS because of disease progression were estimated to have a life expectancy of 10.5 months from the start of treatment, based on existing literature. 33 Patients who did not receive ACT following debulking surgery were estimated to have a life expectancy of 2.7 months, based on prior trial evidence. 22 
Costs
Costs associated with treating 15,000 women in the hypothetical cohort included the cost of the hospitalization associated with debulking surgery (with or without major complications), 34 the base cost of the debulking procedure plus a weighted average of the cost of additional procedures 35 (using procedure rates reported for each arm of SCORPION), the cost of major late (930 days postsurgery) complications, 34 and the cost of chemotherapy administered (Table 2) . 36 Administrative billing codes used to estimate costs are available in Supplemental Table 1 , http://links.lww.com/IGC/ A720. All costs were inflation adjusted to 2015 US dollars using the medical care components of the Consumer Price Index from the Bureau of Labor Statistics. 37 Chemotherapy costs were calculated based on treatment with paclitaxel and carboplatin, administered every 21 days. Chemotherapy dosing was calculated as 175 mg/m 2 for paclitaxel and an area under the curve of 5 for carboplatin, based on treatment in the SCORPION trial and current guidelines (Table  S1 , http://links.lww.com/IGC/A720). 24, 38 We assumed that all patients who initiated chemotherapy completed all cycles (3 cycles of NACT + 3 cycles of ACT among NACT patients; 6 cycles of ACT among PDS patients). Because there were no statistically significant differences in the incidence of chemotherapy-related toxicities between groups in SCORPION, these events were not incorporated into our model.
Quality of Life
To calculate average QALYs associated with each treatment alternative, EORTC Cancer Quality of Life Questionnaire (QLQ-C30) scores from the SCORPION trial were converted to EuroQol 5-Dimension utility weights using a published algorithm. 39 Utility weights from the published 24 †The differing probabilities of receiving adjuvant chemotherapy between patients who did or did not experience late complications following debulking surgery reflect the actual differences in receipt of adjuvant chemotherapy in the SCORPION trial. Table S1 for individual procedures and probabilities.
†No late complications were observed among NACT patients in Fagotti et al 24 ; the costs of late complications were assumed to be equal to those of PDS when varying this probability in sensitivity analysis.
ASP, Average sales price; HCUP, Hospital Cost and Utilization Project. literature 40 were used for patients who did not undergo ACT following debulking surgery and patients who did not undergo IDS following NACT because these patients did not complete quality-of-life assessments in SCORPION. 24 Qualityadjusted life-years were calculated as a weighted average of utility weights for the time spent in each subbranch of the decision tree (Table 3) .
Threshold Analysis
In addition to the main analysis, a threshold analysis was performed to identify the overall survival among NACT patients that would result in cost-effectiveness at $50,000/ QALY and $100,000/QALY WTP thresholds. The threshold analysis assumed that quality of life for all time beyond the initial 1-year time horizon was equal between treatment arms and associated with a utility weight of 0.83, taken from prior literature. 40 Costs incurred beyond the 1-year time horizon were assumed to be equal between treatment alternatives.
Sensitivity Analyses
A probabilistic sensitivity analysis with 10,000 Monte Carlo simulations was performed using Crystal Ball (Oracle, Redwood City, CA) to characterize the uncertainty of our model. Factors varied in sensitivity analyses including event probabilities, costs, and utility weights, with distributions selected based on published guidance. 41 Costs were varied along a F distribution, with > and A parameters estimated using the method of moments, using an SE of 10% of the mean. Utilities were varied along a triangular distribution, using base-case utility weights as the most likely value and minimum and maximum values of T0.05. Events probabilities were varied along a A distribution, with > and A parameters estimated using the incidence of events reported in the SCORPION trial. 24 Because no late complications were observed in the NACT group, we used the cost of late complications observed in the PDS group as the estimate for the cost of late complications in the NACT group to inform sensitivity analyses. Similarly, we assumed the probability of receiving ACT following IDS with late complications was equal to the probability observed in the PDS group.
In addition to the probabilistic sensitivity analysis, we conducted a scenario analysis replacing the utility weights calculated from SCORPION with literature-based utilities (Table S2 , http://links.lww.com/IGC/A721). 25, 40, 42 Because this study analyzed a hypothetical cohort and contained no individual patient data, it did not meet the criteria of human subjects research and was therefore exempt from institutional review board approval.
RESULTS
In a hypothetical cohort of 15,000 AEOC cases, NACT was associated with $142 million in costs savings, 1098 fewer AEOC-related deaths, 1355 additional life-years, and 1715 additional QALYs (Table 4 ). Because it both was cost-saving and produced superior outcomes relative to PDS, NACT was considered the dominant treatment strategy over the 1-year time horizon. On average, treatment with NACT cost approximately $9452 per patient less than treatment with PDS and was associated with a 7.3% lower risk of postoperative death.
Our threshold analysis revealed that NACT would remain cost-effective at $50,000/QALY and $100,000/QALY WTP thresholds if overall survival among PDS patients was no more than 0.23 years (2.73 months) and 0.11 years (1.37 months) greater than that of NACT patients, respectively.
In probabilistic sensitivity analysis, NACT was the dominant strategy in 99.3% of 10,000 Monte Carlo simulations. Of the 10,000 simulations, 72 (0.7%) resulted in NACT being associated with lower costs and lower QALYs, compared with PDS (quadrant 3). The remaining simulations resulted in lower costs and higher QALYs associated with NACT, compared with PDS (quadrant 4), making NACT the dominant strategy (Fig. 2) .
Results of the scenario analysis using literature-based utility weights did not meaningfully alter our results (Table S3 , http://links.lww.com/IGC/A722).
DISCUSSION
In this cost-effectiveness study of short-term outcomes associated with treatment with NACT versus PDS for bulky AEOC, NACT was associated with lower costs, fewer perioperative and postoperative deaths, and increased life-years *Utility weight applied to threshold analysis (survival differences beyond 1 year).
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and QALYs, making it the dominant treatment strategy for all outcomes assessed. To our knowledge, this is the first cost-effectiveness study to assess NACT versus PDS using data from a randomized controlled trial (RCT) conducted in an aggressive surgical setting, which may better reflect surgical practices in the United States, compared with prior RCTs. Evaluating cost-effectiveness in an aggressive surgical setting is critical to obtaining estimates that are relevant to a US payer, given concerns about generalizability of existing RCTs in terms of potential differences in upfront surgical effort. If debulking surgery in the United States is typically more aggressive, then cost-effectiveness studies using estimates from CHORUS or EORTC 55971 likely underestimate the true cost of PDS procedures and associated complications. Comparison of our results to those of a prior cost-effectiveness study using input data from EORTC 55971 supports this hypothesis. 25 Concerns around lack of generalizability associated with existing RCTs make consideration of differences in overall survival an important component in evaluating the cost-effectiveness of NACT for bulky AEOC because more aggressive upfront surgery that results in resection to minimal or no gross residual disease may be associated with a longterm survival advantage. In the absence of data on overall survival from the SCORPION trial, we attempted to address this point using a threshold analysis, which calculated the maximum survival difference for which NACT would remain cost-effective, given the cost savings we estimated for the 1-year time horizon. We found that, although NACT was associated with cost savings and superior QALY outcomes under the assumption of no survival differences, if PDS provided a survival advantage of more than 1.37 months over NACT, PDS would be cost-effective at a $100,000/QALY WTP threshold. If PDS provided a survival advantage of more than 2.73 months, PDS would be cost-effective at a $50,000/QALY WTP threshold.
The survival differences estimated in our threshold analysis are smaller than differences observed in some US nonrandomized studies, which have observed 3 to 10 months of additional survival with PDS. 43, 44 However, it is important to note that unmeasured confounding present in these studies likely introduces bias that makes survival differences appear larger than they actually are. In addition, results of the threshold analysis are driven by the low overall cost of treatment with NACT and PDS relative to our willingness to pay. Although treatment with PDS costs approximately 56% more than NACT, the absolute difference in cost per patient between the 2 treatments (roughly $9500) is much lower than the $50,000 or $100,000 typically used as the willingness to pay to gain an additional year of life in perfect health (1 QALY). In this way, patient preferences with respect to tradeoffs between overall survival and quality of life may be a more important consideration than cost for treatment decisions, given the low absolute cost and low cost differential. This is an important area for future research.
This study is not without limitations. There are currently no ongoing randomized studies in the United States. Therefore, our model relied on inputs derived from preliminary results of the Italian SCORPION trial. Trial patients may not be representative of the United States; however, SCOR-PION represents the only existing randomized comparison of NACT and PDS using surgical practices similar to those in the United States. Data from a randomized setting are especially important when comparing outcomes between patients treated with NACT versus PDS because of the potential for strong confounding in observational studies. In practice, treatment with NACT is often selected for patients with more widely distributed tumors and those whose poor health status is a contraindication for upfront surgery, 43Y46 both of which are associated with poor prognosis. As a result, obtaining unbiased estimates of overall survival for this comparison in a nonexperimental setting is extremely difficult. This lack of conclusive evidence on overall survival differences between NACT and PDS also made calculating cost-effectiveness over a longer time horizon infeasible. However, given that there is no evidence of differences in quality of life or costs between NACT and PDS beyond 1 year posttreatment, the cost-effectiveness of NACT at varying estimates of overall survival can still be interpreted using the threshold analysis presented.
In addition to generalizability, the SCORPION trial is limited by its small sample size, resulting in a lack of precision in event probabilities. In addition, some rare events may not have been captured. To address this, we performed a probabilistic sensitivity analysis, which suggested that our model was robust to this uncertainty in our inputs.
There are currently no published algorithms to convert EORTC QLQ-C30 scores to utility weights for patients with advanced ovarian cancer. In order to calculate utility weights from the EORTC QLQ-C30 scores reported in the SCORPION trial, we used a published algorithm developed in a population of patients with nonYsmall cell lung cancer. 39 The validity of this algorithm in an ovarian cancer population is unknown. As a scenario analysis, we used utility weights from published literature, with ovarian cancerYspecific utilities used whenever possible. 25, 40, 42 The results of this analysis were very similar to the main analysis.
In conclusion, our findings indicate that in an aggressive surgical paradigm NACT is the dominant treatment alternative to PDS if survival between the 2 treatments is equal. However, these conclusions are sensitive to differences in overall survival between treatments because of the low cost of both NACT and PDS relative to typical WTP thresholds. Although NACT is more cost-effective in the 1-year time horizon, a 2.7-month increase in survival, relative to NACT, would result in PDS being cost-effective at typical WTP thresholds. Future analyses will be important once data on overall survival become available from an RCT using an aggressive cytoreduction strategy.
